We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
27 hedge funds and large institutions have $405K invested in ImmunoCellular Therapeutics, Ltd. in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 0 closing their positions.
New
Increased
Maintained
Reduced
Closed
35% more funds holding
Funds holding: 20 → 27 (+7)
13% less capital invested
Capital invested by funds: $464K → $405K (-$59K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Holders
27
Holders Change
+7
Holders Change %
+35%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$30.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$14.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.57K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.05K |
| 5 |
NFG
Next Financial Group
Houston,
Texas
|
+$691 |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$15.3K |
| 2 |
VF
Virtu Financial
New York
|
-$12.3K |
| 3 |
Invesco
Atlanta,
Georgia
|
-$316 |
| 4 |
Morgan Stanley
New York
|
-$6 |
